Johnson & Johnson - Net Worth and Insider Trading

Johnson & Johnson Net Worth

The estimated net worth of Johnson & Johnson is at least $263 Million dollars as of 2024-11-29. Johnson & Johnson is the 10% Owner of Protagonist Therapeutics Inc and owns about 2,449,183 shares of Protagonist Therapeutics Inc (PTGX) stock worth over $110 Million. Johnson & Johnson is the 10% Owner of Fusion Pharmaceuticals Inc and owns about 3,670,516 shares of Fusion Pharmaceuticals Inc (FUSN) stock worth over $79 Million. Johnson & Johnson is also the 10% Owner of CVRx Inc and owns about 4,103,430 shares of CVRx Inc (CVRX) stock worth over $63 Million. Besides these, Johnson & Johnson also holds Nevro Corp (NVRO) , Minerva Neurosciences Inc (NERV) , Neoleukin Therapeutics Inc (NLTX) , Achillion Pharmaceuticals Inc (ACHN) . Details can be seen in Johnson & Johnson's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Johnson & Johnson has not made any transactions after 2024-02-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Johnson & Johnson

Johnson & Johnson Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Johnson & Johnson owns 18 companies in total, including Fusion Pharmaceuticals Inc (FUSN) , Provention Bio Inc (PRVB) , and Inspire Medical Systems Inc (INSP) among others .

Click here to see the complete history of Johnson & Johnson’s form 4 insider trades.

Insider Ownership Summary of Johnson & Johnson

Ticker	Comapny	Transaction Date	Type of Owner
FUSN	Fusion Pharmaceuticals Inc	2020-06-30	10 percent owner
PRVB	Provention Bio Inc	2018-07-03	10 percent owner
INSP	Inspire Medical Systems Inc	2018-05-02	10 percent owner
		2017-11-20	10 percent owner
		2015-03-13	10 percent owner
		2016-08-16	10 percent owner
		2015-06-08	10 percent owner
		2015-08-11	10 percent owner
		2014-05-01	10 percent owner
		2014-02-04	10 percent owner
		2010-12-31	10 percent owner
		2010-04-14	10 percent owner
		2007-03-27	10 percent owner
		2003-12-31	10 percent owner
		2024-02-16	10 percent owner
		2022-11-09	10 percent owner
		2014-02-04	10 percent owner
		2023-05-03	10 percent owner

Johnson & Johnson Latest Holdings Summary

Johnson & Johnson currently owns a total of 7 stocks. Among these stocks, Johnson & Johnson owns 2,449,183 shares of Protagonist Therapeutics Inc (PTGX) as of August 16, 2016, with a value of $110 Million and a weighting of 41.91%. Johnson & Johnson owns 3,670,516 shares of Fusion Pharmaceuticals Inc (FUSN) as of June 30, 2020, with a value of $79 Million and a weighting of 30.11%. Johnson & Johnson also owns 4,103,430 shares of CVRx Inc (CVRX) as of February 16, 2024, with a value of $63 Million and a weighting of 23.91%. The other 4 stocks Nevro Corp (NVRO) , Minerva Neurosciences Inc (NERV) , Neoleukin Therapeutics Inc (NLTX) , Achillion Pharmaceuticals Inc (ACHN) have a combined weighting of 4.07% among all his current holdings.

Latest Holdings of Johnson & Johnson

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
PTGX	Protagonist Therapeutics Inc	2016-08-16	2,449,183	44.95	110,090,776
FUSN	Fusion Pharmaceuticals Inc	2020-06-30	3,670,516	21.55	79,099,620
CVRX	CVRx Inc	2024-02-16	4,103,430	15.31	62,823,513
NVRO	Nevro Corp	2015-06-08	2,066,740	4.58	9,465,669
NERV	Minerva Neurosciences Inc	2015-03-13	562,520	2.15	1,209,418
NLTX	Neoleukin Therapeutics Inc	2015-08-11	5,000	3.49	17,450
ACHN	Achillion Pharmaceuticals Inc	2017-11-20	0	6.76	0

Holding Weightings of Johnson & Johnson

Johnson & Johnson Form 4 Trading Tracker

According to the SEC Form 4 filings, Johnson & Johnson has made a total of 0 transactions in Protagonist Therapeutics Inc (PTGX) over the past 5 years. The most-recent trade in Protagonist Therapeutics Inc is the acquisition of 583,333 shares on August 16, 2016, which cost Johnson & Johnson around $7 Million.

According to the SEC Form 4 filings, Johnson & Johnson has made a total of 1 transactions in Fusion Pharmaceuticals Inc (FUSN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Fusion Pharmaceuticals Inc is the acquisition of 725,000 shares on June 30, 2020, which cost Johnson & Johnson around $12 Million.

According to the SEC Form 4 filings, Johnson & Johnson has made a total of 1 transactions in CVRx Inc (CVRX) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in CVRx Inc is the sale of 3,725 shares on February 16, 2024, which brought Johnson & Johnson around $96,142.

More details on Johnson & Johnson's insider transactions can be found in the Insider Trading History of Johnson & Johnson table.

Insider Trading History of Johnson & Johnson

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Johnson & Johnson Trading Performance

GuruFocus tracks the stock performance after each of Johnson & Johnson's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Johnson & Johnson is 27.87%. GuruFocus also compares Johnson & Johnson's trading performance to market benchmark return within the same time period. The performance of stocks bought by Johnson & Johnson within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Johnson & Johnson's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Johnson & Johnson

Average Return

Average return per transaction

Outperforming Transactions

2 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	0.7
Relative Return to S&P 500(%)	-0.9

Johnson & Johnson Ownership Network

Ownership Network List of Johnson & Johnson

No Data

Ownership Network Relation of Johnson & Johnson

Johnson & Johnson Owned Company Details

What does Fusion Pharmaceuticals Inc do?

Who are the key executives at Fusion Pharmaceuticals Inc?

Johnson & Johnson is the 10 percent owner of Fusion Pharmaceuticals Inc. Other key executives at Fusion Pharmaceuticals Inc include Chief Medical Officer Dmitri Bobilev , director & Chief Executive Officer John Valliant , and Chief Scientific Officer Christopher P Leamon .

Fusion Pharmaceuticals Inc (FUSN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Fusion Pharmaceuticals Inc (FUSN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Fusion Pharmaceuticals Inc (FUSN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Fusion Pharmaceuticals Inc (FUSN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fusion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Provention Bio Inc do?

Who are the key executives at Provention Bio Inc?

Johnson & Johnson is the 10 percent owner of Provention Bio Inc. Other key executives at Provention Bio Inc include 10 percent owner Sessa Capital (master), L.p. , director & 10 percent owner & Chief Scientific Officer Francisco Leon , and director & 10 percent owner & President and CEO Ashleigh Palmer .

Provention Bio Inc (PRVB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Provention Bio Inc (PRVB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Provention Bio Inc (PRVB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Provention Bio Inc (PRVB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Provention Bio Inc Insider Transactions

No Available Data

What does Inspire Medical Systems Inc do?

Who are the key executives at Inspire Medical Systems Inc?

Johnson & Johnson is the 10 percent owner of Inspire Medical Systems Inc. Other key executives at Inspire Medical Systems Inc include Chief Technology Officer John Rondoni , Senior VP. & Sales & Marketing Randy Ban , and Chief Financial Officer Richard Buchholz .

Inspire Medical Systems Inc (INSP) Insider Trades Summary

Over the past 18 months, Johnson & Johnson made no insider transaction in Inspire Medical Systems Inc (INSP). Other recent insider transactions involving Inspire Medical Systems Inc (INSP) include a net sale of 6,984 shares made by Jerry C Griffin , a net sale of 26,726 shares made by John Rondoni , and a net sale of 127,992 shares made by Timothy P. Herbert .

In summary, during the past 3 months, insiders sold 9,534 shares of Inspire Medical Systems Inc (INSP) in total and bought 0 shares, with a net sale of 9,534 shares. During the past 18 months, 213,792 shares of Inspire Medical Systems Inc (INSP) were sold and 100 shares were bought by its insiders, resulting in a net sale of 213,692 shares.

Inspire Medical Systems Inc (INSP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Inspire Medical Systems Inc Insider Transactions

No Available Data

What does Achillion Pharmaceuticals Inc do?

Who are the key executives at Achillion Pharmaceuticals Inc?

Johnson & Johnson is the 10 percent owner of Achillion Pharmaceuticals Inc. Other key executives at Achillion Pharmaceuticals Inc include EVP & Chief Commercial Officer Paul E Firuta , EVP & Chief Medical Officer Steven Zelenkofske , and General Counsel Martha E Manning .

Achillion Pharmaceuticals Inc (ACHN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achillion Pharmaceuticals Inc (ACHN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achillion Pharmaceuticals Inc (ACHN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achillion Pharmaceuticals Inc (ACHN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achillion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Minerva Neurosciences Inc do?

Who are the key executives at Minerva Neurosciences Inc?

Johnson & Johnson is the 10 percent owner of Minerva Neurosciences Inc. Other key executives at Minerva Neurosciences Inc include 10 percent owner Ag Boehringer , 10 percent owner Boehringer Ingelheim International Gmbh , and EVP and Head of R&D Remy Luthringer .

Minerva Neurosciences Inc (NERV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Minerva Neurosciences Inc (NERV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Minerva Neurosciences Inc (NERV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Minerva Neurosciences Inc (NERV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Minerva Neurosciences Inc Insider Transactions

No Available Data

What does Protagonist Therapeutics Inc do?

Who are the key executives at Protagonist Therapeutics Inc?

Johnson & Johnson is the 10 percent owner of Protagonist Therapeutics Inc. Other key executives at Protagonist Therapeutics Inc include Chief Medical Officer Arturo Md Molina , Chief Development Officer Suneel Gupta , and director & President and CEO Patel Dinesh V Ph D .

Protagonist Therapeutics Inc (PTGX) Insider Trades Summary

Over the past 18 months, Johnson & Johnson made no insider transaction in Protagonist Therapeutics Inc (PTGX). Other recent insider transactions involving Protagonist Therapeutics Inc (PTGX) include a net sale of 265,000 shares made by Patel Dinesh V Ph D , a net sale of 36,975 shares made by William D. Waddill , and a net sale of 39,624 shares made by Asif Ali .

In summary, during the past 3 months, insiders sold 278,266 shares of Protagonist Therapeutics Inc (PTGX) in total and bought 0 shares, with a net sale of 278,266 shares. During the past 18 months, 504,510 shares of Protagonist Therapeutics Inc (PTGX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 504,510 shares.

Protagonist Therapeutics Inc (PTGX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Protagonist Therapeutics Inc Insider Transactions

No Available Data

What does Nevro Corp do?

Who are the key executives at Nevro Corp?

Johnson & Johnson is the 10 percent owner of Nevro Corp. Other key executives at Nevro Corp include Chief Commercial Officer Greg Siller , President & CEO Kevin R Thornal , and Chief Accounting Officer Richard B. Carter .

Nevro Corp (NVRO) Insider Trades Summary

Over the past 18 months, Johnson & Johnson made no insider transaction in Nevro Corp (NVRO). Other recent insider transactions involving Nevro Corp (NVRO) include a net purchase of 7,500 shares made by Shawn Mccormick ,

In summary, during the past 3 months, insiders sold 0 shares of Nevro Corp (NVRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Nevro Corp (NVRO) were sold and 7,500 shares were bought by its insiders, resulting in a net purchase of 7,500 shares.

Nevro Corp (NVRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nevro Corp Insider Transactions

No Available Data

What does Neoleukin Therapeutics Inc do?

Who are the key executives at Neoleukin Therapeutics Inc?

Johnson & Johnson is the 10 percent owner of Neoleukin Therapeutics Inc. Other key executives at Neoleukin Therapeutics Inc include 10 percent owner Baker Bros. Advisors Lp , Principal Accounting Officer Sean Michael Smith , and Chief Medical Officer Priti Patel .

Neoleukin Therapeutics Inc (NLTX) Insider Trades Summary

Over the past 18 months, Johnson & Johnson made no insider transaction in Neoleukin Therapeutics Inc (NLTX). Other recent insider transactions involving Neoleukin Therapeutics Inc (NLTX) include a net purchase of 2,285,342 shares made by Baker Bros. Advisors Lp , and a net sale of 1,323 shares made by Sean Michael Smith .

In summary, during the past 3 months, insiders sold 0 shares of Neoleukin Therapeutics Inc (NLTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 66 shares of Neoleukin Therapeutics Inc (NLTX) were sold and 114,267 shares were bought by its insiders, resulting in a net purchase of 114,201 shares.

Neoleukin Therapeutics Inc (NLTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neoleukin Therapeutics Inc Insider Transactions

No Available Data

What does Aldeyra Therapeutics Inc do?

Who are the key executives at Aldeyra Therapeutics Inc?

Johnson & Johnson is the 10 percent owner of Aldeyra Therapeutics Inc. Other key executives at Aldeyra Therapeutics Inc include Chief Development Officer Stephen Machatha , See Remarks Bruce Greenberg , and 10 percent owner Perceptive Life Sciences Master Fund Ltd .

Aldeyra Therapeutics Inc (ALDX) Insider Trades Summary

Over the past 18 months, Johnson & Johnson made no insider transaction in Aldeyra Therapeutics Inc (ALDX). Other recent insider transactions involving Aldeyra Therapeutics Inc (ALDX) include a net sale of 2,074,234 shares made by Perceptive Life Sciences Master Fund Ltd , a net sale of 57,346 shares made by Stephen Machatha , and a net sale of 37,236 shares made by Bruce Greenberg .

In summary, during the past 3 months, insiders sold 0 shares of Aldeyra Therapeutics Inc (ALDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,034,319 shares of Aldeyra Therapeutics Inc (ALDX) were sold and 682,265 shares were bought by its insiders, resulting in a net sale of 2,352,054 shares.

Aldeyra Therapeutics Inc (ALDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aldeyra Therapeutics Inc Insider Transactions

No Available Data

What does Genocea Biosciences Inc do?

Who are the key executives at Genocea Biosciences Inc?

Johnson & Johnson is the 10 percent owner of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , director & President and CEO William D Clark , and CHIEF FINANCIAL OFFICER Diantha Duvall .

Genocea Biosciences Inc (GNCAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GNCAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GNCAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genocea Biosciences Inc (GNCAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genocea Biosciences Inc Insider Transactions

No Available Data

What does Universal Biosensors Inc do?

Who are the key executives at Universal Biosensors Inc?

Johnson & Johnson is the 10 percent owner of Universal Biosensors Inc. Other key executives at Universal Biosensors Inc include 10 percent owner Vf High Conviction Fund , 10 percent owner Cvc Ltd , and Chief Executive Officer John Stewart Sharman .

Universal Biosensors Inc (UVBIL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Universal Biosensors Inc (UVBIL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Universal Biosensors Inc (UVBIL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Universal Biosensors Inc (UVBIL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Universal Biosensors Inc Insider Transactions

No Available Data

What does Tengion Inc do?

Who are the key executives at Tengion Inc?

Johnson & Johnson is the 10 percent owner of Tengion Inc. Other key executives at Tengion Inc include director & President and CEO John L Miclot , Chf. Fin. Offr & VP Fin. A Brian Davis , and 10 percent owner Medtronic Inc .

Tengion Inc (TNGNQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Tengion Inc (TNGNQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Tengion Inc (TNGNQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Tengion Inc (TNGNQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tengion Inc Insider Transactions

No Available Data

What does OPKO Health Inc do?

Who are the key executives at OPKO Health Inc?

Johnson & Johnson is the 10 percent owner of OPKO Health Inc. Other key executives at OPKO Health Inc include 10 percent owner Frost Phillip Md Et Al , director & Chief Innovation Officer Gary J. Nabel , and director & Vice Chairman and President Elias A. Zerhouni .

OPKO Health Inc (OPK) Insider Trades Summary

Over the past 18 months, Johnson & Johnson made no insider transaction in OPKO Health Inc (OPK). Other recent insider transactions involving OPKO Health Inc (OPK) include a net purchase of 11,960,894 shares made by Frost Phillip Md Et Al , a net purchase of 400,010 shares made by Hsiao Jane Ph D , and a net purchase of 50,000 shares made by Pfenniger Richard C Jr .

In summary, during the past 3 months, insiders sold 0 shares of OPKO Health Inc (OPK) in total and bought 760,366 shares, with a net purchase of 760,366 shares. During the past 18 months, 0 shares of OPKO Health Inc (OPK) were sold and 13,252,388 shares were bought by its insiders, resulting in a net purchase of 13,252,388 shares.

OPKO Health Inc (OPK)'s detailed insider trading history can be found in Insider Trading Tracker table.

OPKO Health Inc Insider Transactions

No Available Data

What does Protein Polymer Technologies Inc do?

Who are the key executives at Protein Polymer Technologies Inc?

Johnson & Johnson is the 10 percent owner of Protein Polymer Technologies Inc.

Protein Polymer Technologies Inc (PPTIQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Protein Polymer Technologies Inc (PPTIQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Protein Polymer Technologies Inc (PPTIQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Protein Polymer Technologies Inc (PPTIQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Protein Polymer Technologies Inc Insider Transactions

No Available Data

What does CVRx Inc do?

Who are the key executives at CVRx Inc?

Johnson & Johnson is the 10 percent owner of CVRx Inc. Other key executives at CVRx Inc include Chief Marketing Officer Paul Verrastro , 10 percent owner Johnson & Johnson Innovation - Jjdc, Inc. , and SVP & U.S. Sales Craig E. Palmer .

CVRx Inc (CVRX) Insider Trades Summary

Over the past 18 months, Johnson & Johnson made 1 insider transaction in CVRx Inc (CVRX) with a net sale of 3,725. Other recent insider transactions involving CVRx Inc (CVRX) include a net sale of 5,725 shares made by Paul Verrastro , a net purchase of 8,500 shares made by Joseph P Slattery , and a net purchase of 30,000 shares made by Kevin Hykes .

In summary, during the past 3 months, insiders sold 1,430 shares of CVRx Inc (CVRX) in total and bought 0 shares, with a net sale of 1,430 shares. During the past 18 months, 9,450 shares of CVRx Inc (CVRX) were sold and 38,500 shares were bought by its insiders, resulting in a net purchase of 29,050 shares.

CVRx Inc (CVRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

CVRx Inc Insider Transactions

No Available Data

What does MeiraGTx Holdings PLC do?

Who are the key executives at MeiraGTx Holdings PLC?

Johnson & Johnson is the 10 percent owner of MeiraGTx Holdings PLC. Other key executives at MeiraGTx Holdings PLC include director & 10 percent owner Perceptive Life Sciences Master Fund Ltd , 10 percent owner Johnson & Johnson Innovation - Jjdc, Inc. , and Chief Medical Officer Robert K Zeldin .

MeiraGTx Holdings PLC (MGTX) Insider Trades Summary

Over the past 18 months, Johnson & Johnson made no insider transaction in MeiraGTx Holdings PLC (MGTX). Other recent insider transactions involving MeiraGTx Holdings PLC (MGTX) include a net purchase of 1,250,000 shares made by Perceptive Life Sciences Master Fund Ltd ,

In summary, during the past 3 months, insiders sold 0 shares of MeiraGTx Holdings PLC (MGTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MeiraGTx Holdings PLC (MGTX) were sold and 1,250,000 shares were bought by its insiders, resulting in a net purchase of 1,250,000 shares.

MeiraGTx Holdings PLC (MGTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

MeiraGTx Holdings PLC Insider Transactions

No Available Data

What does Genocea Biosciences Inc do?

Who are the key executives at Genocea Biosciences Inc?

Johnson & Johnson is the 10 percent owner of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , EVP PHARM SCI & MFG Stapleton Raymond D Jr , and 10 percent owner Paul Edward Walker .

Genocea Biosciences Inc (GGNNQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GGNNQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GGNNQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genocea Biosciences Inc (GGNNQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genocea Biosciences Inc Insider Transactions

No Available Data

What does Kenvue Inc do?

Who are the key executives at Kenvue Inc?

Johnson & Johnson is the 10 percent owner of Kenvue Inc. Other key executives at Kenvue Inc include Group President & NALA Kathy Widmer , Chief Tech & Data Officer Bernardo Tavares , and Chief Scientific Officer Caroline Tillett .

Kenvue Inc (KVUE) Insider Trades Summary

Over the past 18 months, Johnson & Johnson made no insider transaction in Kenvue Inc (KVUE). Other recent insider transactions involving Kenvue Inc (KVUE) include a net purchase of 5,598 shares made by Allison Richard E Jr ,

In summary, during the past 3 months, insiders sold 0 shares of Kenvue Inc (KVUE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kenvue Inc (KVUE) were sold and 5,598 shares were bought by its insiders, resulting in a net purchase of 5,598 shares.

Kenvue Inc (KVUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kenvue Inc Insider Transactions

No Available Data

Johnson & Johnson Mailing Address

Above is the net worth, insider trading, and ownership report for Johnson & Johnson. You might contact Johnson & Johnson via mailing address: One Johnson & Johnson Plz, New Brunswick Nj 08933.

Discussions on Johnson & Johnson

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.